Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$10K
Filings
32
Firms Hired
1
Active Period
2018–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Issues related to the following bills: S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin.
Client expense: — · Firm income: —
Matched citations: HR 3269
Issues related to the following bills: S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin.
Client expense: — · Firm income: —
Matched citations: S.2276
Issues related to the following bills: S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin.
Client expense: — · Firm income: —
Matched citations: S.4189
Issues related to the following bills: oAffordable Drug Manufacturing Act (no bill number yet) - To establish an Office of Drug Manufacturing within HHS and for them to manufacture generic drugs that the federal government has licensed. oS.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. oH.R.3269/S.2276: ETHIC Act - would curb the practice of patent thicketing, bringing competition to the domestic biosimilars market and increasing access to lower cost treatments and cures.
Client expense: — · Firm income: —
Matched citations: S.2276
Issues related to the following bills: S.1040: Drug Competition Enhancement Act - Prohibits product hopping which stifles generic and biosimilar competition to extend monopoly pricing. It explicitly defines and regulates these under the Federal Trade Commission S.1041: Affordable Prescriptions for Patients Act - Limits how brand-name drug companies use patents to block competition from cheaper biosimilar or generic versions of biologic drugs by reducing the number of patents drug companies can use to delay cheaper alternatives from entering the market - making medicines more affordable and accessible. A brand-name drug company could then only sue using up to 20 patents when a competitor applies to sell a biosimilar. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act - Stops pharmaceutical companies from abusing the citizen petition process to file sham petitions to block or delay generic or biosimilar drug approvals. S.1096: Preserve Access to Affordable Generics and Biosimilars Act - Bans pay-to-delay or killer acquisitions. Brand name drug manufacturers cannot pay generic manufacturers to delay-to-market any competitive biosimilar or interchangeable biologic products. S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. HR 7854: Medicines for the People Act - To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Additionally, issues related to an FTC settlement.
Client expense: — · Firm income: —
Matched citations: HR 3269
Issues related to the following bills: S.1040: Drug Competition Enhancement Act - Prohibits product hopping which stifles generic and biosimilar competition to extend monopoly pricing. It explicitly defines and regulates these under the Federal Trade Commission S.1041: Affordable Prescriptions for Patients Act - Limits how brand-name drug companies use patents to block competition from cheaper biosimilar or generic versions of biologic drugs by reducing the number of patents drug companies can use to delay cheaper alternatives from entering the market - making medicines more affordable and accessible. A brand-name drug company could then only sue using up to 20 patents when a competitor applies to sell a biosimilar. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act - Stops pharmaceutical companies from abusing the citizen petition process to file sham petitions to block or delay generic or biosimilar drug approvals. S.1096: Preserve Access to Affordable Generics and Biosimilars Act - Bans pay-to-delay or killer acquisitions. Brand name drug manufacturers cannot pay generic manufacturers to delay-to-market any competitive biosimilar or interchangeable biologic products. S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. HR 7854: Medicines for the People Act - To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Additionally, issues related to an FTC settlement.
Client expense: — · Firm income: —
Matched citations: HR 7854
Drug Competition Enhancement Act
2026 · first_quarter · Firm: T1INTERNATIONAL USA
Issues related to the following bills: S.1040: Drug Competition Enhancement Act - Prohibits product hopping which stifles generic and biosimilar competition to extend monopoly pricing. It explicitly defines and regulates these under the Federal Trade Commission S.1041: Affordable Prescriptions for Patients Act - Limits how brand-name drug companies use patents to block competition from cheaper biosimilar or generic versions of biologic drugs by reducing the number of patents drug companies can use to delay cheaper alternatives from entering the market - making medicines more affordable and accessible. A brand-name drug company could then only sue using up to 20 patents when a competitor applies to sell a biosimilar. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act - Stops pharmaceutical companies from abusing the citizen petition process to file sham petitions to block or delay generic or biosimilar drug approvals. S.1096: Preserve Access to Affordable Generics and Biosimilars Act - Bans pay-to-delay or killer acquisitions. Brand name drug manufacturers cannot pay generic manufacturers to delay-to-market any competitive biosimilar or interchangeable biologic products. S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. HR 7854: Medicines for the People Act - To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Additionally, issues related to an FTC settlement.
Client expense: — · Firm income: —
Matched citations: S.1040
Affordable Prescriptions for Patients Act
2026 · first_quarter · Firm: T1INTERNATIONAL USA
Issues related to the following bills: S.1040: Drug Competition Enhancement Act - Prohibits product hopping which stifles generic and biosimilar competition to extend monopoly pricing. It explicitly defines and regulates these under the Federal Trade Commission S.1041: Affordable Prescriptions for Patients Act - Limits how brand-name drug companies use patents to block competition from cheaper biosimilar or generic versions of biologic drugs by reducing the number of patents drug companies can use to delay cheaper alternatives from entering the market - making medicines more affordable and accessible. A brand-name drug company could then only sue using up to 20 patents when a competitor applies to sell a biosimilar. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act - Stops pharmaceutical companies from abusing the citizen petition process to file sham petitions to block or delay generic or biosimilar drug approvals. S.1096: Preserve Access to Affordable Generics and Biosimilars Act - Bans pay-to-delay or killer acquisitions. Brand name drug manufacturers cannot pay generic manufacturers to delay-to-market any competitive biosimilar or interchangeable biologic products. S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. HR 7854: Medicines for the People Act - To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Additionally, issues related to an FTC settlement.
Client expense: — · Firm income: —
Matched citations: S.1041
Issues related to the following bills: S.1040: Drug Competition Enhancement Act - Prohibits product hopping which stifles generic and biosimilar competition to extend monopoly pricing. It explicitly defines and regulates these under the Federal Trade Commission S.1041: Affordable Prescriptions for Patients Act - Limits how brand-name drug companies use patents to block competition from cheaper biosimilar or generic versions of biologic drugs by reducing the number of patents drug companies can use to delay cheaper alternatives from entering the market - making medicines more affordable and accessible. A brand-name drug company could then only sue using up to 20 patents when a competitor applies to sell a biosimilar. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act - Stops pharmaceutical companies from abusing the citizen petition process to file sham petitions to block or delay generic or biosimilar drug approvals. S.1096: Preserve Access to Affordable Generics and Biosimilars Act - Bans pay-to-delay or killer acquisitions. Brand name drug manufacturers cannot pay generic manufacturers to delay-to-market any competitive biosimilar or interchangeable biologic products. S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. HR 7854: Medicines for the People Act - To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Additionally, issues related to an FTC settlement.
Client expense: — · Firm income: —
Matched citations: S.1095
Preserve Access to Affordable Generics and Biosimilars Act
2026 · first_quarter · Firm: T1INTERNATIONAL USA
Issues related to the following bills: S.1040: Drug Competition Enhancement Act - Prohibits product hopping which stifles generic and biosimilar competition to extend monopoly pricing. It explicitly defines and regulates these under the Federal Trade Commission S.1041: Affordable Prescriptions for Patients Act - Limits how brand-name drug companies use patents to block competition from cheaper biosimilar or generic versions of biologic drugs by reducing the number of patents drug companies can use to delay cheaper alternatives from entering the market - making medicines more affordable and accessible. A brand-name drug company could then only sue using up to 20 patents when a competitor applies to sell a biosimilar. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act - Stops pharmaceutical companies from abusing the citizen petition process to file sham petitions to block or delay generic or biosimilar drug approvals. S.1096: Preserve Access to Affordable Generics and Biosimilars Act - Bans pay-to-delay or killer acquisitions. Brand name drug manufacturers cannot pay generic manufacturers to delay-to-market any competitive biosimilar or interchangeable biologic products. S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. HR 7854: Medicines for the People Act - To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Additionally, issues related to an FTC settlement.
Client expense: — · Firm income: —
Matched citations: S.1096
Issues related to the following bills: S.1040: Drug Competition Enhancement Act - Prohibits product hopping which stifles generic and biosimilar competition to extend monopoly pricing. It explicitly defines and regulates these under the Federal Trade Commission S.1041: Affordable Prescriptions for Patients Act - Limits how brand-name drug companies use patents to block competition from cheaper biosimilar or generic versions of biologic drugs by reducing the number of patents drug companies can use to delay cheaper alternatives from entering the market - making medicines more affordable and accessible. A brand-name drug company could then only sue using up to 20 patents when a competitor applies to sell a biosimilar. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act - Stops pharmaceutical companies from abusing the citizen petition process to file sham petitions to block or delay generic or biosimilar drug approvals. S.1096: Preserve Access to Affordable Generics and Biosimilars Act - Bans pay-to-delay or killer acquisitions. Brand name drug manufacturers cannot pay generic manufacturers to delay-to-market any competitive biosimilar or interchangeable biologic products. S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. HR 7854: Medicines for the People Act - To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Additionally, issues related to an FTC settlement.
Client expense: — · Firm income: —
Matched citations: S.2276
Issues related to the following bills: S.1040: Drug Competition Enhancement Act - Prohibits product hopping which stifles generic and biosimilar competition to extend monopoly pricing. It explicitly defines and regulates these under the Federal Trade Commission S.1041: Affordable Prescriptions for Patients Act - Limits how brand-name drug companies use patents to block competition from cheaper biosimilar or generic versions of biologic drugs by reducing the number of patents drug companies can use to delay cheaper alternatives from entering the market - making medicines more affordable and accessible. A brand-name drug company could then only sue using up to 20 patents when a competitor applies to sell a biosimilar. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act - Stops pharmaceutical companies from abusing the citizen petition process to file sham petitions to block or delay generic or biosimilar drug approvals. S.1096: Preserve Access to Affordable Generics and Biosimilars Act - Bans pay-to-delay or killer acquisitions. Brand name drug manufacturers cannot pay generic manufacturers to delay-to-market any competitive biosimilar or interchangeable biologic products. S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. HR 7854: Medicines for the People Act - To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Additionally, issues related to an FTC settlement.
Client expense: — · Firm income: —
Matched citations: S.4189
Patent Eligibility Restoration Act of 2025
2025 · fourth_quarter · Firm: T1INTERNATIONAL USA
Issues related to the following bills: oS.1040: Drug Competition Enhancement Act oS.1041: Affordable Prescriptions for Patients Act oS.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act oS.1096: Preserve Access to Affordable Generics and Biosimilars Act oH.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act oH.R.3152/S.1546: Patent Eligibility Restoration (PERA) Act oH.R.3269: ETHIC Act
Client expense: — · Firm income: —
Matched citations: S.1546
Issues related to the following bills: oS.1040: Drug Competition Enhancement Act oS.1041: Affordable Prescriptions for Patients Act oS.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act oS.1096: Preserve Access to Affordable Generics and Biosimilars Act oH.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act oH.R.3152/S.1546: Patent Eligibility Restoration (PERA) Act oH.R.3269: ETHIC Act
Client expense: — · Firm income: —
Matched citations: S.1553
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · third_quarter · Firm: T1INTERNATIONAL USA
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Client expense: — · Firm income: —
Matched citations: HR 1
Patent Eligibility Restoration Act of 2025
2025 · third_quarter · Firm: T1INTERNATIONAL USA
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Client expense: — · Firm income: —
Matched citations: H.R.3152
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Client expense: — · Firm income: —
Matched citations: H.R.3160
Fair Prescription Drug Prices for Americans Act
2025 · third_quarter · Firm: T1INTERNATIONAL USA
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Client expense: — · Firm income: —
Matched citations: S.1218
Drug Competition Enhancement Act
2025 · third_quarter · Firm: T1INTERNATIONAL USA
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Client expense: — · Firm income: —
Matched citations: S.1040
Affordable Prescriptions for Patients Act
2025 · third_quarter · Firm: T1INTERNATIONAL USA
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Client expense: — · Firm income: —
Matched citations: S.1041
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Client expense: — · Firm income: —
Matched citations: S.1095
Preserve Access to Affordable Generics and Biosimilars Act
2025 · third_quarter · Firm: T1INTERNATIONAL USA
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Client expense: — · Firm income: —
Matched citations: S.1096
Patent Eligibility Restoration Act of 2025
2025 · third_quarter · Firm: T1INTERNATIONAL USA
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Client expense: — · Firm income: —
Matched citations: S.1546
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Client expense: — · Firm income: —
Matched citations: S.1553
End Price Gouging for Medications Act
2025 · third_quarter · Firm: T1INTERNATIONAL USA
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Client expense: — · Firm income: —
Matched citations: S.1753
Source: Senate LDA